Skip to content Skip to footer
Subscribe Now
NEWS

Natera Reports Publication of Signatera MRD Test Results for Resected Metastatic Colorectal Cancer in JAMA Oncology

Shots: Natera has reported the publication of data on Signatera, a personalized MRD test for resected colorectal liver metastases (CRLM), in JAMA Oncology, with findings also presented at the ESMO GI 2026 The analysis incl. 298 pts from the GALAXY trial, an observational arm of CIRCULATE-Japan, assessing outcomes by MRD status & adj. CT (ACT) use…
July 6, 2026

Read more

TOP 20

Top 20 Diagnostics Companies of 2026

Shots:  The global diagnostics market is rapidly evolving through AI-powered imaging, molecular testing, precision medicine, and digital pathology solutions. In 2025, Siemens Healthineers led the industry with $20.54B in diagnostics revenue, followed by Roche at $17.52B and GE HealthCare at $17.49B, reflecting the growing adoption of advanced imaging, lab automation, and AI-driven diagnostics across global…
May 29, 2026

Read more

NEWS

Natera Launches Zenith Genomics in the US to Diagnose Rare Diseases

Shots: Natera has reported the commercial launch of Zenith genomics, a next-generation whole genome sequencing (WGS) assay designed to enhance the detection of rare diseases in the US The platform combines whole genome sequencing with long-read sequencing confirmation to detect genomic features such as tandem repeat expansions, supporting diagnosis of rare & ultra-rare conditions, &…
March 13, 2026

Read more

NEWS

Natera Seeks US FDA Approval for Signatera Cdx To Support MRD-Guided Treatment in Bladder Cancer

Shots: The US FDA has received a premarket approval (PMA) application of Signatera CDx for the detection of molecular residual disease (MRD) in pts with muscle-invasive bladder cancer (MIBC) who may benefit from treatment with Tecentriq (atezolizumab) Submission was supported by the P-III (IMvigor011) trial, which met its 1EP & showed that Signatera-guided therapy improved…
February 2, 2026

Read more

NEWS

Natera Acquires Foresight Diagnostics for ~$450M to Strengthen Ultrasensitive MRD Testing in Solid Tumors & Lymphoma

Shots: Natera has acquired Foresight Diagnostics, adding its PhasED-Seq phased variant technology with LOD95 of 0.3ppm & detection below 0.1ppm, further enhancing Natera’s capabilities in solid tumor MRD and expanding its IP portfolio of >500 issued/pending patents As per the agreement, Natera completed the acquisition in an all-stock transaction incl. $275M upfront & up to…
December 8, 2025

Read more

TOP 20

Top 20 Diagnostics Companies of 2025 

Top 20 Diagnostics Companies of 2025  Shots:  Driven by continuous innovation and enhanced precision, the diagnostic industry is advancing rapidly, transforming the way healthcare is delivered  In 2025, the global diagnostic testing market is valued at approximately $207.96B in 2025 and is projected to grow to around $272.9B by 2034, reflecting a CAGR of 3%.…
May 29, 2025

Read more